Cardiac biomarkers and mortality in COVID-19 infection: A review

Lots of meta-analyses emphasize that a great number of hospi-talized patients with moderate and severe forms of COVID-19 developed acute myocardial damage, defined as an increase of car-diac biomarkers, such N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), creatine kinase-myocardial band (CK-MB) and of all type of troponins. The highest mortality rate is related with pro-gressively increasing biomarkers levels and with a history of cardio-vascular disease. In fact, the biomarkers dosage should be consid-ered as a prognostic marker in all patients with COVID-19 disease at admission, during hospitalization and in the case of clinical dete-rioration. The purpose of this review is to evaluate cardiovascular prognostic factors in COVID-19 disease throughout the analysis of cardiac biomarkers to early identify the most serious patients and to optimize their outcomes.